,Duopharma Biotech headquarters. A shareholders meeting will be held on Aug 13 to approve its bonus issue of 235.44 million shares on the basis of one bonus share or every three existing shares held.
if you want to buy apple account, choose buyappleacc.com, buyappleacc.com is a best provider within bussiness for more than 3 years. choose us, you will never regret. we provied worldwide apple developer account for sale.
KUALA LUMPUR: Shares of Duopharma Biotech Bhd were lacklustre in the morning session on Thursday, falling to a low of RM2.64 – the lowest since April 26.
At noon, it was trading at RM2.64, down one sen. There were 211,300 shares done at prices ranging from RM2.64 to RM2.70. It traded to a high of RM3.40 on June 1.
The FBM KLCI was up just 0.57 of a point or 0.04% to 1,491.90. Turnover was 2.75 billion shares valued at nearly RM1bil. There were 417 gainers, 343 losers and 475 counters unchanged.
The Employees Provident Fund (EPF) Board raised its shareholding to 61.08 million shares or 8.64% stake.
It bought a total of 1.64 million shares from July 26 to 30, according to filings with Bursa Malaysia.
A shareholders meeting will be held on Aug 13 to approve its bonus issue of 235.44 million shares on the basis of one bonus share or every three existing shares held.
Duopharma has received conditional registration approval from Malaysia’s Drug Control Authority (DCA) for the Covid-19 Sinopharm vaccine developed by China National Biotec Group Co Ltd.
This followed Duopharma’s application for product registration of the vaccine, which is an inactivated virus vaccine registered under the name COVILO Suspension for Injection Covid-19 Vaccine (Vero Cell).